GEMINI DRC Ph1, Multicenter, Open-label, Single-dose, Dose-escalation Study in Patients with Geographic Atrophy (GA) Secondary to Dry AMD to Evaluate the Safety, Tolerability, Pharmacodynamics, and Immunogenicity of Intravitreal Injections of GEM103